Meeting
2021 Gastrointestinal Cancers Symposium
Results of a phase II trial of ramucirumab plus irinotecan as second-line treatment for patients with advanced gastric cancer (HGCSG 1603).
Authors
Yasuyuki Kawamoto
Division of Cancer Center, Hokkaido University Hospital, Sapporo, Japan
Yasuyuki Kawamoto , Satoshi Yuki , Kentaro Sawada , Michio Nakamura , Osamu Muto , Susumu Sogabe , Yoshiaki Shindo , Atsushi Ishiguro , Atsushi Sato , Yasushi Tsuji , Masayoshi Dazai , Hiroyuki Okuda , Takahide Sasaki , Kazuaki Harada , Shintaro Nakano , Hiroshi Nakatsumi , Mari Sekiguchi , Yuh Sakata , Naoya Sakamoto , Yoshito Komatsu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session: Esophageal and Gastric Cancer
Track
Esophageal and Gastric Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
jRCTs011180029
Citation
J Clin Oncol 39, 2021 (suppl 3; abstr 217)
DOI
10.1200/JCO.2021.39.3_suppl.217
Abstract #
217
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2019 Gastrointestinal Cancers Symposium
HGCSG 1603: Phase II study of ramucirumab and irinotecan combination therapy as second-line treatment in patients with metastatic or advanced gastric cancer.
First Author: Atsushi Ishiguro
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Preliminary results of surufatinib (Suru) plus standard chemotherapy (ChT) as second line (2L) treatment of advanced gastric cancer (aGC): A single-arm, phase 2 clinical trial.
First Author: Ting Han
First Author: Sylvie Lorenzen
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Updated results from the phase II study: Efficacy and safety of anlotinib plus sintilimab as second-line treatment for patients with advanced biliary tract cancers.
First Author: Shuiling Jin